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j Abstract Background We re-
cently reported a randomised
controlled trial on the efﬁcacy of
strength training and the b2-
adrenergic agonist albuterol in
patients with facioscapulohumeral
muscular dystrophy (FSHD).
Strength training and albuterol
appeared safe interventions with
limited positive effect on muscle
strength and volume. We concur-
rently explored the prevalence and
the characteristics of pain and
fatigue in the participating FSHD
patients, because these are proba-
bly underreported but clinically
relevant symptoms in this disor-
der. Next, we studied the effects of
albuterol and strength training on
pain, experienced fatigue, health-
related functional status and psy-
chological distress. Methods Sixty-
ﬁve patients were randomised to
strength training of elbow ﬂexors
and ankle dorsiﬂexors or non-
training. After 26 weeks, albuterol
(sustained-release, 8 mg bid) was
added in a randomised, double-
blind, placebo-controlled design.
Outcomes comprised self-reported
pain, experienced fatigue, func-
tional status and psychological
distress obtained with validated
questionnaires at 52 weeks.
Results Eighty percent of patients
reported chronic persistent or
periodic, multifocal pains. Thirty-
four percent of the participants
were severely fatigued. Strength
training and albuterol failed to
have a signiﬁcant effect on all
outcomes. Conclusions Pain and
fatigue are important features in
FSHD. Strength training and
albuterol do not have a positive or
negative effect on pain, experi-
enced fatigue, functional status
and psychological distress.
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In descriptions of facioscapulohumeral muscular
dystrophy (FSHD) pain and fatigue are rarely men-
tioned as important clinical features of the condition.
However, a questionnaire-based survey in 270 French
and one in 84 Dutch members of patient support
groups indicated that pain is present in 50–75% of
patients [6, 22]. Bushby et al. reported four adult
patients with FSHD in whom pain was a presenting
complaint and remained their most disabling symp-
tom [10]. In a recent questionnaire-based survey, 61%
of 139 Dutch FSHD patients were severely fatigued
[19]. Their experienced fatigue severity was associated
with the severity of functional impairments in daily
life. Actually, pain and fatigue seem to be important
symptoms in FSHD; and they are not only underre-
ported, but probably also undertreated. In patients
with slowly progressive neuromuscular diseases, such
as FSHD, combinations of muscle weakness, pain,
fatigue, problems with locomotion and body weight
can lead to reduced physical activity and a sedentary
lifestyle [26]. Physical inactivity has a negative inﬂu-
ence on quality of life and health outcomes [26].
In FSHD the decline in muscle strength and mass is
progressive over years and follows in general a rec-
ognizable sequence of muscle involvement. However,
there is a large, unexplained, interindividual vari-
ability in rate of progression, even within families
sharing the same mutation [30, 36, 41]. The variable
course within families and the typical asymmetric
weakness has led to the hypothesis that daily exertion
might be responsible for disease progression [9, 18].
Uncontrolled studies on the effects of strength train-
ing in neuromuscular disorders, although including
only 13 FSHD patients, suggested a positive effect of
strength training and did not point towards extra
susceptibility for muscle overstrain [1, 25, 28, 39]. The
results of a pilot study and a subsequent randomised,
controlled trial in FSHD patients with the b2-adren-
ergic agonist albuterol were indicative for an anabolic
effect that wears off with prolonged use [20, 21]. In
animals and healthy persons the strength-increasing
effect of b2-adrenergic agonists can be augmented
when it is administered in combination with resis-
tance exercise [11, 14, 16, 42]. We previously reported
a randomised controlled trial in which we evaluated
the efﬁcacy of a moderate-intensity strength training
program and albuterol in FSHD [35]. Strength train-
ing and albuterol were well tolerated and appeared
safe interventions with limited positive effects on
muscle strength and volume. Contrary to our expec-
tation no synergistic effects between training and
albuterol were detected; also no antagonistic effect
was observed.
A strength training program could potentially in-
duce muscle soreness caused by exercise-induced
muscle damage or pain as a result of increased strain
on the tendoskeletal apparatus. The imposed extra
physical activity could lead to an increase in experi-
enced fatigue caused by a physical overload, as well as
a decrease caused by a better physical condition.
There is no information available on the effects of
b2-adrenergic agonists, such as albuterol, on muscle
endurance or on experienced fatigue. Theoretically,
albuterol could result in reduced fatigability via in-
creased muscle strength and mass, but also in a de-
crease in muscle endurance by slow-to-fast muscle
ﬁbre type transformation [43]. Ideally, both inter-
ventions—strength training and albuterol—should
result in less disability and a better quality of life.
The objectives of this study were: (1) to explore the
prevalence, magnitude and other characteristics of
pain and experienced fatigue in the group of FSHD
patients participating in the previously reported,
randomised controlled trial [35], and (2) to study the
effects of albuterol and strength training on self-re-
ported pain, experienced fatigue, functional status
and psychological distress in these patients.
Methods
Sixty-ﬁve genetically conﬁrmed, adult FSHD patients were rando-
mised to strength training of elbow ﬂexors and ankle dorsiﬂexors
or non-training. After 26 weeks, albuterol (sustained-release, 8 mg
bid) was added in a double-blind, placebo-controlled design.
Treatment was continued for another 26 weeks. For the effect of
training the primary outcome measure was the maximum volun-
tary isometric strength (MVIC) of the elbow ﬂexors and ankle
dorsiﬂexors. Main secondary outcomes were muscle endurance and
dynamic muscle strength of elbow ﬂexors and ankle dorsiﬂexors.
To evaluate the effect of albuterol the MVIC of eight large muscle
groups, including elbow ﬂexors and ankle dorsiﬂexors, was used as
primary outcome measure. Main secondary outcome measures
were muscle endurance and the total body skeletal muscle volume
estimated by stereological CT method. For an extensive description
of the subjects and interventions, the study design (see also Fig. 1),
the test methods of the primary and main secondary outcomes, we
refer to our previous publication [35]. The local ethics committee
approved the study, and written informed consent was obtained
from all subjects.
j Outcome measures
The outcome measures concerning self-reported pain, experienced
fatigue, health-related functional status and psychological distress
were obtained with widely used, validated and reliable question-
naires and a self-observation list; all described hereafter. The
questionnaires were sent to the participants’ home three weeks
before the baseline (week 0) and ﬁnal visit (52 weeks), and handed
in during these visits. The person who extracted the data from the
questionnaires and made them suitable for statistical analysis was
blinded for the assignment to both interventions.
932Pain
The McGill Pain Questionnaire (MPQ) was used for the assessment
of different aspects of pain [27]. The MPQ is widely used, well
validated and reliable [33, 34]. The main outcome measure for pain
was the magnitude of pain at that moment marked on a visual
analogue scale (VAS); a VAS score of 0 mm indicating no pain, and
100 mm unbearable pain. In the MPQ patients were also asked to
mark in the list of pain descriptors those adjectives that applied
best to their pain. Finally, the MPQ included a whole body outline
to indicate the distribution of the pain, and an inventory of the use
of analgesics. In addition, the participants rated the intensity of
their pain on a daily self-observation list during a two-week period.
Pain severity was rated four times a day on a scale of 0 (no pain) to
4 (severe pain). The daily pain score could range from 0 to 16, and
the 14 daily pain scores were averaged into one Daily Observed
Pain score (DOP) [31].
Experienced fatigue
The main outcome measure for experienced fatigue was the score
on the fatigue severity subscale of the Checklist Individual Strength
(CIS) [37]. In this questionnaire, the patient is asked to score the
following four aspects of fatigue during the previous two weeks:
fatigue severity (8 items), concentration problems (5 items), re-
duced motivation (4 items) and reduced activity (3 items). Each
item is scored on a 7-point Likert scale. Higher scores indicate
higher levels of fatigue, more concentration problems, low moti-
vation and lower levels of activity. A CIS-fatigue subscale score
equal to or higher than 35 identiﬁes abnormal or severe fatigue
[38]. The CIS questionnaire has good reliability and validity,
including discriminative validity [13, 37, 38]. Experienced fatigue
and self-reported activity levels were also measured with the daily
self-observation list. Similar to the Daily Observed Pain score
(DOP), a Daily Observed Fatigue score (DOF) and a Daily Observed
Activity score (DOA) were calculated. A higher DOF score indicates
more experienced fatigue, and a higher DOA score more self-re-
ported activity [31].
Functional status
Health-related functional status was assessed using the original
Sickness Impact Proﬁle (SIP) [8, 17]. Reliability and validity of the
SIP have been evaluated extensively [8, 17]. A total score of general
disability (SIP-total) was calculated by adding the weights of items
in the 12 categories or subscales: sleep/rest, emotional behaviour,
body care/movement, household management, mobility, social
interactions, ambulation, alertness behaviour, communication,
work limitations, recreation/pastimes, and eating. The total SIP
score ranges from 0 to 10,298. A higher score means more dis-
ability.
Psychological distress
The Symptom Checklist-90 (SCL) was used to measure psycho-
logical distress [5]. This scale is widely used, and the reliability and
validity, including discriminative validity are good [5]. The scale
consists of 90 items scored on a 5-point Likert scale, and rates
symptoms as anxiety, depression, sleeping problems and somati-
sation. The total score ranges from 90 to 450. A low total score
reﬂects good psychological well-being, and higher scores indicate
more distress. The Beck Depression Inventory – Primary Care
(BDI-PC) was used as an additional outcome [7]. The BDI-PC was
developed speciﬁcally for evaluating depression in medical patients
by reﬂecting only the cognitive and affective symptoms of
depression, while excluding somatic and performance items that
might be related to medical problems (e.g. tiredness or fatigue,
worries about physical problems). The BDI-PC is a 7-item ques-
tionnaire measuring depression on a 4-point scale ranging from 0
to 3 points per item. A score of 4 or more indicates a depression.
Statistics
To describe the study population at baseline the following methods
or measures were used: (a) two-sided t-tests to test for statistically
signiﬁcant differences (a = 0.05) between subgroups, in case of
continuous variables; (b) v
2 test for nominal variables (a = 0.05);
Qualiﬁcation Visit 
Assessed for eligibility (n=97) 
Baseline Visit week 0 
Randomized (n=65) 
Excluded (n=32) 
Did not meet criteria (n=24)
Personal reasons (n=3) 
Excluded by cardiologist (n=5)
Allocated to NT (n=31)
Received intervention (n=31)
Allocated NT+P (n=16)
Received intervention (n=16)
Final Visit week 52
Discontinued medication (n=1)
side eﬀects
Final Visit week 25
Discontinued medication (n=2),
discontnued trainig (n=1),
side eﬀects
Allocated NT+A (n=15)
Received intervention (n=15)
Allocated T+P (n=19)
Received intervention (n=19)
Allocated T+A (n=15)
Received intervention (n=15)
Allocated to T (n=34)
Received intervention (n=34)
Follow-up Visit week 26 (n=31) Follow-up Visit 26 (n=34)
Final Visit week 52
Discontinued intervention (n=0)
Final Visit week 25
Discontinued medication (n=1),
side eﬀects
Analyzed (n=15) Analyzed (n=19) Analyzed (n=15) Analyzed (n=16)
Fig. 1 Study design and flow of patients through each stage of the study. NT = non-training group, T = training group, P = placebo, and A = albuterol
933and (c) Pearson coefﬁcient (r) for correlations. To retain power
with these relatively small sample sizes, and because of the
explorative nature of this descriptive part of the study, no adjust-
ments were made for the multiple comparisons (at baseline).
The efﬁcacy analyses were performed on an intention-to-treat
basis, such that all randomised subjects were included in the
analyses. A general linear mixed model was used to study possible
differences between the four groups on the outcome measures,
separately. The ﬁxed independent variables were the study ‘‘visit’’
(0, 52 weeks), ‘‘training’’ (yes, no), ‘‘albuterol’’ (yes, no), ‘‘gender’’
(male, female), and ‘‘severity’’ (‡3, 2 trainable muscle groups). Per
patient a random intercept was allowed. To detect differences be-
tween visits related to any of these variables all ﬁrst order inter-
action terms between these variables and ‘‘visit’’ were included.
Higher order interaction terms, except one second order term
(‘‘training’’ * ‘‘albuterol’’ * ‘‘visit’’) were excluded from the model,
as they appeared to be not statistically signiﬁcant (at the level of
a = 0.05). The estimated means and effect sizes (difference in mean
change from baseline analysed by intervention over all treatment
groups) with 95% conﬁdence intervals are presented. Tukey–Kra-
mer adjustments for multiple comparisons were performed.
Results
j Subjects & design
The diagram in Fig. 1 shows the ﬂow of patients
through each stage of the study. Sixty-ﬁve patients
were admitted to the study and randomised. The 25
females and 40 males had a mean age of 40 ± 11 and
37 ± 10 years, respectively. One patient stopped
training, and four patients stopped using their study
medication because of side effects [35]. All the par-
ticipants completed their visits. Each patient had to
complete six questionnaires for the baseline visit
(week 0) and for the ﬁnal visit (week 52). Only 10 of
the 780 questionnaires were not handed in: ﬁve at
baseline, and ﬁve at 52 weeks. The demographic and
baseline characteristics of the patients are presented
in Table 1.
j Baseline characteristics
Pain
Thirteen out of 65 patients (20%) reported on the
MPQ to have no pain complaints at all. The other 52
patients had a VAS ranging from 0 to 83 mm, with a
mean VAS of 16 mm. In the subgroup with pain these
complaints were present for a mean duration of
85 ± 69 months. In 88% of these patients pain com-
plaints had started gradually. Fifty percent of these
patients reported periodic pains; in the other 50%
pain was constantly present with exacerbations. In
73% of patients with pain the complaints were always
localized in the same body regions, with a mean of
4.3 ± 2.7 affected regions. Pain was most frequently
present in the shoulder region, followed by the neck,
lower back and lower leg (Table 2). Pain intensity was
mostly described as mild to moderate, bearable to
discomforting, annoying and tiring. Frequently used
adjectives to characterize the pain were sore, stabbing,
stiff and taut. Only seven patients (11%) used anal-
gesics regularly. Five of these patients used conven-
tional ﬁrst-line analgesics one to four times a week,
and one patient daily. One patient used clonazepam
once a week. Correlation between VAS and DOP
scores were moderate (r = 0.65, p < 0.001). There was
Table 1 Baseline characteristics for the total study group, the pain subgroups and the fatigue subgroups
All patients n = 65 No pain n = 13 With pain n = 52 p-value* Not sev. fatigued n = 43 Severely fatigued n = 22 p-value*
Patient characteristics
Female, % 40 23 42 0.20 35 45 0.42
Age, years 38 ± 10 37 ± 12 38 ± 10 0.66 38 ± 11 38 ± 10 0.79
Pain
VAS, mm 12.9 ± 17.1 0 ± 0 16.1 ± 17.7 0.0018 9.0 ± 14.0 20.6 ± 20.0 0.008
DOP 2.4 ± 2.2 0.4 ± 0.7 3.0 ± 2.2 <0.001 2.0 ± 2.0 3.4 ± 2.6 0.013
Experienced fatigue
CIS—Fatigue 28.8 ± 12.1 23.6 ± 9.7 30.1 ± 12.4 0.09 – – –
CIS—Fatigue ‡35, % 34 15 38 0.16 – – –
DOF 3.4 ± 2.3 2.5 ± 1.3 3.7 ± 2.3 0.07 2.7 ± 1.7 5.1 ± 2.1 <0.001
DOA 6.1 ± 2.0 5.7 ± 1.5 6.3 ± 2.1 0.3 6.3 ± 2.3 5.8 ± 1.4 0.33
Functional status
SIP—Total 708 ± 612 585 ± 537 739 ± 630 0.42 525 ± 526 1,091 ± 594 <0.001
Psychological distress
SCL—Total 117 ± 29 117 ± 37 115 ± 24 0.89 108 ± 15 131 ± 37 <0.001
BDI-PC 1.7 ± 3.0 2.1 ± 4.8 1.6 ± 2.5 0.63 0.9 ± 1.7 3.3 ± 4.3 0.0018
BDI-PC ‡4, % 16 8 18 0.39 7 33 0.008
Values are means ± 1 SD, unless specified differently
*Using v
2 test for comparing percentages and t-test for comparing means
VAS = visual analogue scale; DOP = Daily Observed Pain score; CIS = Checklist Individual Strength; DOF = Daily Observed Fatigue score; DOA = Daily Observed
Activity score; SIP = Sickness Impact Profile; SCL = Symptom Cheklist-90; BDI-PC = Beck Depression Inventory for Primary Care
934no correlation between pain and activity as assessed
with the DOP and DOA scores (r = 0.06, p = 0.66).
Experienced fatigue
Twenty-two patients (34%) had a CIS-fatigue score
equal to or higher than 35 indicating abnormal or
severe fatigue. Also, the mean CIS-fatigue score of
28.8 was indicative for increased fatigue as com-
pared to a group of healthy controls [37]. Mean
scores on the subscales concentrations problems
(10.5 ± 6.7), reduced motivation (10.1 ± 5.0), and
reduced activity (7.8 ± 4.7) were similar or not
signiﬁcantly elevated as compared to healthy con-
trols [37]. There was a moderate correlation between
the CIS-fatigue score and the DOF score (r = 0.59,
p < 0.001). Fatigue and activity as assessed with the
DOF and DOA scores did not correlate (r = )0.05,
p = 0.73).
Functional status and psychological distress
Mean SIP-total score was 708.3 ± 611.7 implying
relatively moderate sickness-related dysfunction in
this group of FSHD patients [17]. The highest mean
scores, indicating more problems, were in the cate-
gories sleep and rest, household management,
ambulation, work limitations, and recreation and
pastimes. Lower scores were found in the subscales
emotional behaviour, body care and movement,
mobility, social interactions, alertness behaviour,
communication and eating.
Mean total and subscales scores of the SCL were
within normal ranges, so there were no indications of
abnormal psychological distress in the population
studied. Sixteen percent of patients had a BDI-PC
score of 4 or more, indicative of a depression. This
percentage is not different from the prevalence of
depression among patients with a medical illness in
primary care settings [40].
Comparison of patients with and without pain
Baseline characteristics and values for the comparison
of patients with and without pain are presented in
Table 1. There was no relationship between the
presence of pain and gender (v
2 = 1.63, p = 0.20).
The mean VAS was not signiﬁcantly different between
males and females (females: 16.4 ± 17.9 mm, males:
10.7 ± 16.3 mm, t-test, p = 0.3). However, the mean
DOP score was signiﬁcantly higher for females (fe-
males 3.4 ± 2.4, males 1.8 ± 1.9, t-test, p = 0.01).
Patients with and without pain were similar regarding
their age. There was a weak correlation for both the
VAS and the DOP scores and the age of patients, older
patients having higher VAS and DOP scores (VAS:
r = 0.28, p = 0.02; DOP: r = 0.30, p = 0.02).
The pain-free subgroup had a not signiﬁcantly
lower mean CIS-fatigue and DOF score (CIS-fatigue:
p = 0.09, DOF: p = 0.07). Fifteen percent of patients
in the pain-free subgroup were severely fatigued as
compared to 38% in the subgroup with pain
(v
2 = 2.46, p = 0.16). The mean DOA, SIP-total, SCL-
total, and BDI-PC scores did not differ signiﬁcantly
between both groups.
Comparison of patients with and without severe fati-
gue
Baseline characteristics and values for the comparison
of patients with and without severe fatigue are pre-
sented in Table 1. There was no relationship between
the presence of severe fatigue and gender (v
2 = 0.65,
p = 0.42). Also, the CIS-fatigue score was indepen-
dent of gender (mean females: 30.7 ± 11.2; males:
27.6 ± 12.6, t-test, p = 0.31). Despite the moderate
correlation between the CIS-fatigue score and the
DOF score (r = 0.59, p < 0.001), there was a slightly,
but signiﬁcantly higher DOF score for females (mean
females: 4.2 ± 1.9, males: 2.8 ± 2.1, t-test, p = 0.01).
Patients in the severely fatigued subgroup had a
similar age as compared to the not severely fatigued
Table 2 Localization of pain as
indicated on the bodily outline of the
McGill Pain Questionnaire
Pain localization Unilateral n Bilateral n Total n Total % Remarks
Face – – 3 5
Neck – – 24 37
Shoulder girdle 13* 20** 33 51 *8 right, 5 left **rhomboid region
Upper arm 5 8 13 20 more frequent ventral side
Fore-arm, wrist, hand 2 7 9 14 including elbow
Abdomen, groin – – 5 8
Back – – 21 32 mainly lower back
Hip region 7 2 9 14
Thigh, upper leg 6 8 14 22 more frequent ventral side
Knee 5 1 6 9
Lower leg, ankle, foot 12 11 23 35 ventral equals dorsal side
Each patient can have multiple localizations
n = number of patients indicating pain on a specific localization
% = number of patients expressed as the percentage of the total study population
935patients. CIS-fatigue and DOF scores showed no
correlation with age (CIS-fatigue: r = 0.11, p = 0.39;
DOF: r = 0.09, p = 0.48).
The severely fatigued subgroup had a signiﬁcantly
higher mean VAS and DOP score (VAS: p = 0.008;
DOP: p = 0.013). Nine percent of patients in the se-
verely fatigued subgroup had no pain as compared to
26% of the not severely fatigued patients (v
2 = 2.46,
p = 0.16). The mean DOA score did not differ sig-
niﬁcantly between both groups. The severely fatigued
subgroup had a signiﬁcantly higher SIP-total score (t-
test, p < 0.001), and higher SCL-total (t-test,
p < 0.001), indicating more functional disability and
more psychological distress. The BDI-PC score was
also signiﬁcantly higher in the severely fatigued pa-
tients (p = 0.002). Thirty-three percent of patients in
the severely fatigued subgroup had a BDI-PC score
‡4, indicative of a depression, as compared to 7% of
those who were not severely fatigued (v
2 = 6.98,
p = 0.008).
j Interventions
Effect of strength training on pain
Patients reported no notable muscle soreness to the
physical therapist during his home visits. Eleven out
of 34 patients in the training group reported increase
of pain in neck and shoulder region at sometime
during these home visits. Five mentioned a period
with elbow complaints. The number of neck-shoulder
and elbow complaints as assessed with the MPQ
questionnaire did not differ between the training and
non-training groups at baseline and at the ﬁnal visit
(Table 3).
After 52 weeks the main outcome measure for
pain—the mean VAS—, and also the mean DOP
scores of the training and non-training groups did not
demonstrate signiﬁcant changes (Table 4).
Effect of strength training on experienced fatigue
In general, patients reported to the physical therapist
that their training-induced muscle fatigue lasted less
than an hour. The training did not induce notable
general fatigue, and they could carry out their daily
activities normally afterwards. One patient stopped
training because of recurring, training-related muscle
soreness and fatigue. She had a second diagnostic
work-up, revealing a mitochondrial myopathy as well
as FSHD.
After 52 weeks the main outcome measure for
experienced fatigue, the mean CIS-fatigue, did not
demonstrate signiﬁcant differences in changes be-
tween the training and non-training groups (Table 4).
The mean DOF score of the patients in the training
groups slightly decreased, while we observed a small
increase in the non-training patients (effect size: )0.7;
CI: )1.5 to )0.01, p = 0.047).
Effect of albuterol on pain and fatigue
Patients were called twice by a neurologist blinded
for treatment allocation to check for initial and
ongoing side effects of the study medication. Patients
did not mention pain or fatigue as possible adverse
effects.
The outcome measures for pain and fatigue of the
albuterol and placebo groups did not change signiﬁ-
cantly between the baseline and ﬁnal visit (Table 4).
Effect of both interventions on functional status and
psychological distress
At the ﬁnal visit the mean SIP-total, and it subscales,
did not demonstrate relevant or signiﬁcant changes
for both the training and non-training groups, and the
albuterol and placebo groups. Also, for all groups the
mean SCL-total and the mean BDI scores did not
change between the baseline and ﬁnal visit (Table 4).
For all outcomes there were no differences between
males and females. No synergistic effects between
training and albuterol were detected; also no antag-
onistic effect was observed.
Discussion
Eighty percent of the participating FSHD patients
reported chronic persistent or periodic pain with a
low to moderate intensity, mostly characterized as
sore, stabbing, stiff and taut. Pains were most fre-
quently present around the shoulders, neck, lower
back and lower legs. There was no relationship be-
tween the presence of pain and gender or age. How-
ever, if pain was present the reported intensity tended
to be slightly higher for female and older patients.
Patients with pain appeared to be more fatigued. The
outcomes for functional status and psychological
distress did not signiﬁcantly differ between those with
and without pain.
Table 3 Number of patients reporting neck, shoulder and elbow (pain)
complaints by training group
Localization Non-training (n = 31) Training (n = 34)
Week 0 Week 52 Week 0 Week 52
Neck-shoulder 22 17 21 19
Elbow 2 1 3 2
936Thirty-four percent of the patients were considered
to be severely fatigued. There was no relationship
between both the presence and the severity of fatigue,
and gender or age. Severely fatigued patients had
signiﬁcantly more pain, more disability, more psy-
chological distress, and more depressive feelings.
However, our data also indicated relatively moderate
sickness-related dysfunction and no indications of
abnormal psychological distress in the total group of
patients studied.
The two interventions, moderate-intensive
strength training and albuterol, did not appear to
have a clear positive or negative effect on pain,
experienced fatigue, functional status or psychological
distress.
The results of the Dutch and French surveys were
rather similar with regard to relative frequency, pat-
tern in time, and localization and other characteristics
of pain [6, 22]. Considering the high relative fre-
quency of pain, it is surprising how little attention this
complaint has received. For all, it raises questions
about the pathophysiology of pain in this disorder. As
suggested, part of the multifocal, often asymmetrical
pains—especially those in the shoulder region and
around the spine—can probably be attributed to
postural problems [10]. Problems induced by the loss
of muscle mass and strength, as pain was most fre-
quently localized in body regions affected early and
most severely in the course of the dystrophic process.
However, a considerable proportion of our patients
reported pain in the thighs and upper legs, and some
patients even mentioned facial pains. We do not know
if pain in these body parts is more myalgic in nature,
as reported previously. Pain is also mentioned in
relation to the onset and exacerbations of the disease
[10, 30]. Myalgic pains and periodic pains could be
due to—a long debated—inﬂammatory component in
the pathophysiology of FSHD [4]. Although inﬂam-
matory changes in muscle are a frequent histological
feature in FSHD [4, 30], the results of metabolic
Table 4 Results of strength training vs. non-training and albuterol vs. placebo on pain, experienced fatigue, functional status and psychological distress
Placebo (n = 35) Albuterol (n = 30) Effect size
NT (n = 16) T (n = 19) NT (n = 15) T (n = 15) T vs. NT A vs. P
Patient characteristic
Female, % 44 42 40 27
Age, years 39 ± 9 36 ± 9 41 ± 12 36 ± 11
Pain
VAS, mm
Week 0 13.4 (4.9–22.0) 9.7 (1.9–17.6) 10.5 (1.6–19.3) 18.5 (9.7–27.4) 2.3 ()6.6 to 11.1) 1.5 ()7.4 to 10.4)
Week 52 9.0 (0.4–17.6) 12.1 (4.2–20.0) 12.0 (3.1–20.9) 17.9 (9.0–26.8) 0.6 0.7
DOP
Week 0 1.9 (0.7–3.0) 2.1 (1.0–3.1) 2.6 (1.4–3.8) 3.2 (2.0–4.4) )0.7 ()1.5 to 0.1) )0.7 ()1.4 to 0.2)
week 52 1.9 (0.8–3.0) 1.9 (0.9–2.9) 2.5 (1.4–3.6) 1.9 (0.8–3.1) 0.1 0.1
Experienced fatigue
CIS—Fatigue
Week 0 27.1 (21.1–33.0) 25.3 (19.8–30.8) 30.5 (24.3–36.6) 33.3 (27.1–39.4) 3.0 ()2.0 to 8.0) )1.5 ()6.5 to 3.5)
Week 52 26.1 (20.0–31.8) 27.4 (22.1–32.6) 28.0 (22.1–33.9) 33.8 (27.9–39.7) 0.2 0.6
DOF
Week 0 3.6 (2.5–4.7) 3.1 (2.0–4.1) 2.7 (1.7–3.8) 4.2 (3.1–5.4) )0.7 ()1.5 to )0.01) 0.1 ()0.7 to 0.8)
Week 52 3.7 (2.7–4.6) 2.7 (1.8–3.6) 3.1 (2.1–4.1) 3.6 (2.6–4.6) 0.047 0.9
Functional status
SIP—Total
Week 0 691 (380–1,001) 613 (328–898) 723 (402–1,043) 834 (513–1,154) 62 ()105 to 229) 20 ()148 to 187)
Week 52 565 (227–903) 530 (220–840) 599 (247–951) 790 (441–1,139) 0.5 0.8
Psychological distress
SCL—Total
Week 0 117 (104–131) 112 (99–124) 116 (102–130) 124 (110–138) 2 ()6t o1 1 ) 3( )6 to 12)
Week 52 111 (101–121) 106 (97–116) 110 (100–121) 123 (112–133) 0.6 0.6
BDI-PC
Week 0 1.9 (0.4–3.4) 0.7 ()0.7–2.1) 2.2 (0.7–3.7) 2.4 (0.8–3.9) 0.6 ()0.5 to 1.6) )0.6 ()1.6 to 0.5)
Week 52 1.5 (0.5–2.5) 0.7 ()0.2–1.6) 1.1 (0.1–2.1) 1.9 (0.9–2.9) 0.3 0.3
Values for age are means ± 1 SD
Mean values (95% CI) for all scores at the baseline (week 0) and final visit (week 52) presented by treatment group (i.e. non-training and placebo, training and
placebo, non-training and albuterol, training and albuterol). As no statistically significant interactions between the two interventions (i.e. training vs. non-training;
albuterol vs. placebo) could be detected, the effect sizes are presented by intervention. The effect sizes (95% CI; p-value) represent the difference in mean change
from baseline, analysed by intervention (i.e. training vs. non-training; albuterol vs. placebo) over all treatment groups.
NT = non-training group; T = training group; P = placebo; and A = albuterol. VAS = visual analogue scale; DOP = Daily Observed Pain score; CIS = Checklist
Individual Strength; DOF = Daily Observed Fatigue score; SIP = Sickness Impact Profile; SCL = Symptom Cheklist-90; BDI-PC = Beck Depression Inventory for
Primary Care
937investigations and muscle biopsies in the previously
reported four patients with myalgic pains did not
indicate any exceptional inﬂammatory response [10].
Moreover, the myalgic pains in these patients hardly
responded to conventional ﬁrst-line analgesics or
anti-inﬂammatory therapy. Unfortunately, pain was
not an outcome measure in a 12-week open-label pilot
trial with prednisone in eight FSHD patients [32].
The presence of pain did not seem to have an
important inﬂuence on disability and psychological
distress; as opposed to the presence of severe expe-
rienced fatigue, which was clearly associated with
more disability, more psychological distress and more
depressive feelings. The proportion of patients with a
possible depression was signiﬁcantly higher in the
severely fatigued subgroup as compared to the other
patients. Severe fatigue could not be seen as merely a
sign of depression, as 66% of the severely fatigued
patients had normal scores on the depression inven-
tory. However, it appears likely that in the state of
depression fatigue related to FSHD is experienced as
more severe. So, one should consider a depression in
FSHD patients with excessive fatigue.
In a recent questionnaire-based survey 61% (CI:
53–69%) of 139 Dutch FSHD patients were severely
fatigued versus 34% (CI: 22–46%) in our study [19].
Both studies used identical versions of the CIS ques-
tionnaire, and deﬁned severe fatigue by the same cut-
off score. The difference in the proportion of severely
fatigued patients might be due to selection in both
studies. The questionnaire-based survey was speciﬁ-
cally aimed at problems associated with fatigue,
potentially leading to an overestimation if non-
responders tended to be less fatigued. Our study
might underestimate fatigue as a problem, as patients
were only eligible if they were willing to train if
allocated to the training group, and were able to walk
independently, potentially excluding the most fati-
gued and most affected patients. Kalkman et al. also
found an association between the experienced fatigue
severity and functional impairments in daily life [19].
Recently, a 12-week low-intensity aerobic exercise
program in eight FSHD patients improved their aer-
obic capacity without signs of muscle damage [29].
Self-reported fatigue did not change. Regrettably, this
small study lacked a randomised controlled or case-
controlled design, and fatigue severity was not
quantitated.
Experienced fatigue has been deﬁned as an
overwhelming sense of tiredness, lack of energy and
feeling of exhaustion [23]. It is not the same as
muscle weakness or muscle fatigability [23]. Muscle
fatigability has been deﬁned as the failure to sustain
the force of muscle contraction, and is also called
peripheral fatigue [12]. We believe that experienced
fatigue in patients with a muscle disease is not
merely caused by their muscle weakness and muscle
fatigability alone. Central fatigue, characterized by an
enhanced perception of effort and limited endurance
of sustained physical and mental activities, might
play a part as well [12]. Fatigue might even be an
independent determinant of disability. We did not
predeﬁne a measure for disease severity, so at this
moment we cannot answer the important question
on the relations between experienced fatigue, the
severity of the dystrophic process and functional
disability.
We recently reported the primary and main sec-
ondary outcomes of this randomised controlled trial
in which we demonstrated that in FSHD strength
training and albuterol are well tolerated and safe
interventions with limited positive effect on muscle
strength and volume [35]. In the design of this study
self-reported pain, experienced fatigue, functional
status and psychological distress were predeﬁned as
explorative outcome measures.
The very limited positive effects of the strength
training program on muscle strength and the absence
of any detectable effects on experienced fatigue,
functional status and psychological distress could
reﬂect the inability of the diseased neuromuscular and
cardiorespiratory system to respond with normal
adaptations to the applied training stimulus. How-
ever, part of this lack of response could also be due to
the speciﬁcity of the training [15, 24]. The physio-
logical adaptations to training are speciﬁc to muscle
actions involved, speed of movement, range of mo-
tion, muscle groups trained, energy systems involved
and intensity and volume of training [3]. This means
that a training program with dynamic exercises in-
creases dynamic strength more than isometric
strength, and vice versa. This phenomenon of speci-
ﬁcity of training also has implications for the sensi-
tivity of the outcome measures: e.g. the positive effect
of a dynamic strength training program may be cap-
tured by using a dynamic evaluation technique, and
might be missed using an isometric strength measure,
a functional test (e.g. walking), or a functional dis-
ability questionnaire. Of course, the secondary out-
comes not demonstrating any relevant or signiﬁcant
changes may also be due to the small number of
muscle groups trained. The American College of
Sports Medicine recommends exercising eight to ten
major muscle groups to come to an effective training
stimulus [2]. All other recommendations to come to
an effective, standardized, but safe and individualized
exercise prescription were met. Based on our experi-
ence guardedly exercising eight to ten major muscle
groups in neuromuscular patients does actually seem
feasible. And ﬁnally, the FSHD population in this
study turned out to have relatively moderate sickness-
related dysfunction and no indications of abnormal
938psychological distress, so in retrospect perhaps one
could hardly expect relevant changes.
However, in this trial no signs of overuse, such as a
decline in strength measures or training-related in-
crease in pain or fatigue, were seen. This is of major
clinical importance, because these ﬁndings do not
support the hypothesis of extra risk for muscle strain
in FSHD. Still, an extra liability for overwork weak-
ness in more severely affected FSHD patients is not
excluded. Based on our experience we tell our FSHD
patients that ‘normal’ participation in sports and
work appears not to harm their muscles but there is
insufﬁcient evidence to establish that it offers beneﬁt.
And, that there is insufﬁcient evidence for general
prescription of exercise programmes in FSHD.
Pain and fatigue are indeed frequent and clinically
relevant symptoms in FSHD. More work is necessary
to understand their pathophysiology, to study their
relation with disease severity and functional disabil-
ity, and to explore possible treatment strategies. Now
that concise strength training of a few muscle groups
has proven safe, a study on the effect of more com-
prehensive training programs designed to target goals
more meaningful to these patients seems rational.
And, although albuterol (SR capsules, 8 mg twice
daily) did not have any effect on fatigue, functional
status, and psychological distress, the limited positive
effect on muscle strength and volume, and the good
tolerability are sufﬁcient ground for studies exploring
alternative dosing regimens, and combinations with
other ergogenic medication.
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